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A B S T R A C T
Chronic Coxiella burnetii endocarditis usually develops in people with underlying heart disease and
accounts for 60–70% of chronic Q fever. Onset is generally insidious and manifestations are atypical. The
authors report a case of Coxiella burnetii prosthetic valve endocarditis in a 53 years- old patient with
recurrent mechanical valve dehiscence on mitral position. He lived in a rural area with sheep and goats on
the surroundings. During a 9 year- period, he was submitted to three cardiac mitral valve surgeries two of
which with no Q fever diagnosis suspicion. Diagnosis was based on a positive serology test (Indirect
imunoﬂuorescence). Treatment consisted in a combination of prolonged course of hydroxychloroquine
plus doxycycline and surgical replacement of the mitral valve, with a favorable outcome. With this case
report, the authors pretend to highlight the not always expected diagnosis of Q fever endocarditis. If not
considered, Coxiella burnetii endocarditis may lead to multiple cardiac surgeries, greater morbidity and
potentially death.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Caused by Coxiella burnetii, an obligate intracellular Gram-
negative bacterium, Q fever can be acute or chronic. Long-term
sequelae are beginning to gain acceptance as a third category of
this zoonotic disease [1]. Endocarditis usually develops in people
with underlying heart disease and accounts for 60–70% of chronic
Q fever cases [2]. Onset is generally insidious and manifestations
are atypical as fever can be absent [3], and vegetations can be
unapparent or small [4,5]. Additionally, exposure to Coxiella
burnetii may be difﬁcult to ascertain.
The authors report a case of a prosthetic valve endocarditis
caused by Coxiella burnetii in a 53 year- old patient with recurrent
mechanical valve dehiscence. We consider this case of major
importance to highlight that even if endocarditis is the most
common manifestation of chronic Q fever it is still a rare disease
and can be difﬁcult to diagnose as its clinical course is variable.* Correspondence to: Rua Alfredo Pereira, no 209, 4560-502 Penaﬁel, Portugal.
E-mail address: ferrazrit@gmail.com (R.V. Ferraz).
http://dx.doi.org/10.1016/j.idcr.2016.09.005
2214-2509/ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article unCase report
A case of a 53-year old patient with a past history of
transfusional hepatitis C and a splenectomy at the age of 23,
who was admitted in the Infectious Diseases Department of a
Portuguese Hospital in October 2015 because of a recent onset of
fever, dyspnea, fatigue and non productive cough.
The patient’s previous relevant medical history started in June
2004, at the age of 41 years old, when he presented with heart
failure symptoms due to mitral stenosis. In October 2005 mitral-
valve replacement with a mechanical Medtronic valve was
performed.
Five months later (in March, 2006), patient began to have
anorexia, fatigue, progressive dyspnea on exertion, paroxysmal
nocturnal dyspnoea and peripheral edema.
Transesophageal echocardiogram revealed a severe mitral
insufﬁciency secondary to dehiscence of the prosthesis and a
new intervention was performed in August 2006 to correct the leak
without valve replacement.
Six months later he was again admitted for progressively
worsening dyspnoea, asthenia and palpitations with one month
duration and fever (38–39 C) in the previous week. Atrialder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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revealed slight dilation of the left cavities and right atrium, with
preserved ejection fraction and new partial dehiscence of the
prosthesis with elevation of the transprothesic gradient (43/
15 mmHg) causing severe mitral insufﬁciency and severe pulmo-
nary hypertension (>100 mmHg). Blood tests revealed leukocytosis
and C-reactive protein elevation. A diagnosis of culture negative
endocarditis was presumed and empirical antimicrobial therapy
was started with rifampin (300 mg po tid), vancomycin (500 mg
bid IV adjusted to blood levels) and gentamicin (500 mg/day IV).
In March 2007 he underwent a third surgical intervention:
mitral valve replacement with St Jude 27 prosthesis and tricuspid
annuloplasty with a Medtronic ring. Microbiological examination
of the excised valve was negative. No pathogen had grown in the
collected blood cultures. He completed 2 weeks of gentamicin and
4 weeks of vancomycin and rifampin and was started on
hypocoagulation with warfarin for his permanent atrial ﬁbrillation.
The outcome was favorable.
In October 2015 (8 years later), patient was referred to the
emergency room of a peripheral hospital with a history of two
weeks duration of persistent non productive cough, myalgia, fever
and worsened dyspnea on exertion. He denied orthopnea,
paroxysmal nocturnal dyspnea, thoracic pain, vomiting, anorexia
or other gastrointestinal or urinary symptoms.
Concerning the patient epidemiological context, he was
retired (used to work in metal processing), lived in a rural area
with sheep and goats on the surroundings but had no pets or any
farm animals in his house. He denied unpasteurized dairy
products consumption and used only bottled water. He also
denied high risk sexual exposures. He reported neither recent
travel nor contact with ill persons. Medications taken on a daily
basis included warfarin, carvedilol (9.375 mg/day), ramipril
(1.25 mg/day), furosemide (20 mg/day), digoxin (0.125 mg/day
except weekends).
On physical examination, patient was febrile (temperature of
38,2 C), blood pressure was 91/62 mmHg, pulse 80 beats per
minute, room air peripheral O2 saturation of 100%, pulmonary
auscultation was normal and cardiac auscultation revealed an
irregular rhythm with a grade III/VI systolic murmur heard at the
base and apex. Dentition was poor, but with no abscesses. No
peripheral oedema, splinter haemorrhages, Osler’s nodes or
Janeway’s lesions were present. The remaining physical examina-
tion was unremarkable.
Blood workup revealed a haemoglobin 9 g/dL, platelets
293.000, leukocytes 10, 95 10^4, 59% neutrophils, 15% lympho-
cytes, C-reactive protein 29,6 mg/L. Aspartate aminotransferase
129 UI/L; alanine aminotransferase 36 UI/L, alkaline phosfatase
63 UI/L, gamaglutamil transferase 32U/L, Lactate dehydrogenase
2822 UI/L, total bilirrubin 2,63 mg/dL. Iron 79 ug/dL, iron binding
capacity 232 ug/dL, ferritin 11 ng/mL, haptoglobin <0.8 g/dL, Vita-
min B12 502 pg/mL, Folic acid 5.4 ng/mL. Renal function was within
normal range. Antinuclear, anti-smooth muscle, antimitochondrial
anti- dsDNA and anti-histone antibodies were all negative.
Ceftriaxone 2 g/daily was started and he was admitted on the
Internal Medicine Department of another Hospital for study. An
Infectious Diseases Consultation was called for case discussion and
complementary exams were suggested, namely: Brucella spp.
(Wright test) and Coxiella burnetti serologies.
The electrocardiogram showed atrial ﬁbrillation, 67 beats per
minute. The Chest X-ray revealed a right pleural effusion. The
transesophageal echocardiogram revealed: dilation of the left
cavities, preserved systolic function with an ejection fraction of
54%, mild aortic insufﬁciency and mitral valve prosthesis with two
regurgitant jets with a moderate periprosthetic leak. Blood
cultures collected did not isolate any pathogen. Serology for
Brucella spp. was negative.Serologies for Coxiella burnetti were positive: IgG antibodies to
phase I were 1:32 768 and IgG antibodies to phase II was 1:16 384.
IgM antibodies to phase I was 1:512 and IgM to phase II was 1:256.
Polymerase chain- reaction (PCR) for Coxiella burnetti was positive
in the blood. Patient was transferred to our hospital.
The diagnosis of Chronic Q fever endocarditis and haemolytic
anemia secondarily to periprosthetic leak were presumed.
Doxycycline (100 mg orally bid) plus hydroxychloroquine
(600 mg/day) were started. Surgery was performed in December
2015 with valve replacement by a mechanical prosthesis ST Jude n
27. The patient was discharged one week after surgery with the
indication to complete therapy with doxycycline plus hydroxy-
chloroquine for at least 24 months. During follow up no events
were reported and 8 months later he is still asymptomatic (no signs
or symptoms of heart failure, serial echocardiography showing a
preserved integrity of the valve).
Discussion
Q fever is a worldwide zoonosis and the most common sources
of human infection are farm animals such as cattle, goats and
sheep, but also cats, rabbits and dogs can be responsible for
infection in an urban context [6]. These mammals, when infected,
can shed the desiccation- resistant form of the organism in urine,
faeces, milk and, especially, birth products [7]. Infection in humans
results from inhalation of contaminated aerosols from these
specimens [8]. Contact with animals, even if indirect, is important
to suggest the diagnosis of Q fever [2]. In Europe, Q fever cases are
more frequently reported in spring and early summer. They may
occur at all ages, but are more frequent in men. Coxiella burnetii is
endemic in Portugal [9]. Mortality occurs in 1–11% of patients with
chronic Q fever [10].
The clinical picture is very unspeciﬁc but it is known that chronic
infection can develop month or years after acute Q fever [11], which
can be asymptomatic. The most common manifestation of chronic
disease is endocarditis and C. burnetii was the leading cause of
negative blood culture prosthetic- valve endocarditis in one study of
men less than 65 years old. Symptoms began gradually as long as 1–
20 years after initial infection [12]. Most cases involve the aortic or
mitral valve in patients with pre-existing valvular disease or
prosthetic valves. Infection can be very indolent without fever [13]
and prosthetic valves have shown little or no evidence of infection in
the valve ring (3 out of 5 patients had no vegetations found) [14].
The major clinical presentation was unexplained illness in a
patient with known valvular disease [13]. The diagnosis can be
delayed due to the protean manifestations of this entity and some
patients have undergone several valve replacements before a
diagnosis was made [13].
This patient was submitted to two surgical interventions of the
mitral valve due to a mechanical valvular leak, one of which was
assumed to be a consequence of a culture-negative endocarditis.
Nine years later, he developed another dehiscence of the same
valve with surgical indication and only at that time a Q fever
serologic test was performed, leading to the diagnosis of Q fever
endocarditis. We admit that this diagnosis was possibly delayed for
all this time and Coxiella burnetii endocarditis of the mitral valve
could have been present as early as 2006 with recurring infections
of the replacement valves until the diagnosis was made serologi-
cally and therapy instituted. Wiener-Well Y. et al. described
9 patients with Q fever endocarditis during a 19-year period, three
(33%) of which were unexpected and diagnosed after elective valve
surgery [3].
Laboratory manifestations include anaemia, elevated erythro-
cyte sedimentation rate and polyclonal hypergammaglobulinemia.
Leukocyte count may be normal, increased or decreased.
Thrombocytopenia and elevated hepatic enzyme levels are
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fever such as rheumatoid factor, anti- smooth muscle, antinuclear
and antimitochondrial antibodies and also positive Coombs’ test
[15] but in this case all the autoimmune tests were negative.
The gold standard for the diagnosis of Q fever is indirect
immunoﬂuorescence (IF). Phase I antibodies are raised in chronic
disease and IF titres IgG to phase I antigen of 1:800 or more is
considered diagnostic for endocarditis [8]. Some authors say that
PCR has low sensitivity in blood and high sensitivity in tissue
samples [5], but there is evidence of high sensitivity and sensibility
of PCR in specialized laboratories [8]. In our patient both serology
and PCR in blood were positive. The recommended treatment for Q
fever endocarditis is doxycycline (100 mg/bid) plus hydroxychlor-
oquine (200 mg tid) until a target of <1:800 for IgG is achieved.
Generally, a minimum of 18 months is needed [16].
According to Million et al. who published the largest cohort of Q
fever endocarditis to date, for prosthetic valve infections, the
optimum management includes a longer course of therapy
(24 months) with doxycycline and hydroxychloroquine [17].
Intolerance to the recommended drugs, namely photosensitivity
can be a problem, and regular heart and eye examinations are
needed [16]. When untreated, the disease is usually fatal and, even
with appropriate treatment, is associated with a mortality of 10% at
ﬁve years [17]. Million et al. identiﬁed that Coxiella burnetii
endocarditis on prosthetic valves (compared with the general
population and with patients with other valvular heart diseases)
was associated with higher mortality, more frequent stroke,
delayed serological cure, need for longer treatment course and
higher risk of relapse [17].
Our patient is still on treatment and free of disease after
8 months of doxycycline plus hydroxychloroquine.
Conclusion
We consider this case of a major importance to highlight the
need to consider the diagnosis of chronic Q fever not only in the
presence of a culture-negative endocarditis but also when
unexplained valvular leaks occur in prosthetic valves. The authors
recommend that all patients with negative blood culture
endocarditis or unexplained dehiscence of prosthetic valves
undergo serological testing for Q fever.
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